Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin D McCormick

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Bioorganic & Medicinal Chemistry Letters|September 17, 2013
Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesityManuel de Lera Ruiz, Junying Zheng, Michael Y Berlin, et al.
Bioorganic & Medicinal Chemistry Letters|March 2, 2010
Reduction of hERG inhibitory activity in the 4-piperidinyl urea series of H3 antagonistsMichael Berlin, Yoon Joo Lee, Christopher W Boyce, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2013
Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonistsQingbei Zeng, Stuart B Rosenblum, Zhaoxia Yang, et al.
Immunity|February 29, 2024
Oligoadenylate synthetase 1 displays dual antiviral mechanisms in driving translational shutdown and protecting interferon productionMunesh K Harioudh, Joseph Perez, Zhenlu Chong, et al.
Journal of the American Medical Directors Association|June 15, 2021
Antibody Responses After mRNA-Based COVID-19 Vaccination in Residential Older Adults: Implications for ReopeningDavid A Nace, Kevin E Kip, John W Mellors, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2002
Identification of a novel, orally bioavailable histamine H(3) receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) templateRobert Aslanian, Mwangi W Mutahi, Neng Yang Shih, et al.
Bioorganic & Medicinal Chemistry Letters|February 22, 2014
Quality by design (QbD) of amide isosteres: 5,5-Disubstituted isoxazolines as potent CRTh2 antagonists with favorable pharmacokinetic and drug-like propertiesDong Xiao, Xiaohong Zhu, Younong Yu, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2005
Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffoldWayne D Vaccaro, Rosy Sher, Michael Berlin, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 15, 2011
Pharmacological characterization of a novel α2C-adrenoceptor agonist N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1, 4-benzoxazin-6-yl]-N-ethyl-N'-methylurea (compound A)Michel R Corboz, Maria A Rivelli, Kevin D McCormick, et al.
Open Forum Infectious Diseases|June 2, 2023
Rapid Emergence of Potentially Transmissible Severe Acute Respiratory Syndrome Coronavirus 2 With Resistance to Combination Monoclonal Antibody TherapyJana L Jacobs, Ghady Haidar, Asma Naqvi, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Bioorganic & Medicinal Chemistry Letters|September 17, 2013
Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesityManuel de Lera Ruiz, Junying Zheng, Michael Y Berlin, et al.
Bioorganic & Medicinal Chemistry Letters|March 2, 2010
Reduction of hERG inhibitory activity in the 4-piperidinyl urea series of H3 antagonistsMichael Berlin, Yoon Joo Lee, Christopher W Boyce, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2013
Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonistsQingbei Zeng, Stuart B Rosenblum, Zhaoxia Yang, et al.
Immunity|February 29, 2024
Oligoadenylate synthetase 1 displays dual antiviral mechanisms in driving translational shutdown and protecting interferon productionMunesh K Harioudh, Joseph Perez, Zhenlu Chong, et al.
Journal of the American Medical Directors Association|June 15, 2021
Antibody Responses After mRNA-Based COVID-19 Vaccination in Residential Older Adults: Implications for ReopeningDavid A Nace, Kevin E Kip, John W Mellors, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2002
Identification of a novel, orally bioavailable histamine H(3) receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) templateRobert Aslanian, Mwangi W Mutahi, Neng Yang Shih, et al.
Bioorganic & Medicinal Chemistry Letters|February 22, 2014
Quality by design (QbD) of amide isosteres: 5,5-Disubstituted isoxazolines as potent CRTh2 antagonists with favorable pharmacokinetic and drug-like propertiesDong Xiao, Xiaohong Zhu, Younong Yu, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2005
Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffoldWayne D Vaccaro, Rosy Sher, Michael Berlin, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 15, 2011
Pharmacological characterization of a novel α2C-adrenoceptor agonist N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1, 4-benzoxazin-6-yl]-N-ethyl-N'-methylurea (compound A)Michel R Corboz, Maria A Rivelli, Kevin D McCormick, et al.
Open Forum Infectious Diseases|June 2, 2023
Rapid Emergence of Potentially Transmissible Severe Acute Respiratory Syndrome Coronavirus 2 With Resistance to Combination Monoclonal Antibody TherapyJana L Jacobs, Ghady Haidar, Asma Naqvi, et al.
Pageof 3